SAFETY DATA SHEET

LUNSUMIO Vials 30 mg/30 ml

SECTION 1. IDENTIFICATION

Product name : LUNSUMIO Vials 30 mg/30 ml
Product code : 00010221576
Common name(s), synonym(s) of the substance : anti-CD20/CD3 TDB
                                                Bispecific human anti-CD20/CD3 TDB antibody

Manufacturer or supplier’s details
Company name of supplier : Genentech, Inc.
Address : 1 DNA Way
           South San Francisco, CA 94080
           USA
Telephone : 001-(650) 225-1000
E-mail address : info.sds@roche.com
Emergency telephone : US Chemtrec phone (800)-424-9300

Recommended use of the chemical and restrictions on use
Recommended use : Formulated pharmaceutical active substance
Restrictions on use : For professional users only.

SECTION 2. HAZARDS IDENTIFICATION

GHS classification in accordance with the OSHA Hazard Communication Standard (29 CFR 1910.1200)
Hazardous properties cannot be ruled out. Always exercise caution and follow good industrial hygiene practices when handling chemicals.

Not a hazardous substance or mixture.

GHS label elements
Hazardous properties cannot be ruled out. Always exercise caution and follow good industrial hygiene practices when handling chemicals.

Not a hazardous substance or mixture.

Other hazards
None known.

SECTION 3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

<table>
<thead>
<tr>
<th>Chemical name</th>
<th>CAS-No.</th>
<th>Concentration (% w/w)</th>
</tr>
</thead>
</table>

1 / 18
SAFETY DATA SHEET

LUNSUMIO Vials 30 mg/30 ml

Version 1.1
Revision Date: 02-06-2023
Date of last issue: 01-04-2021
Date of first issue: 01-04-2021

Mosunetuzumab 1905409-39-3
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1 0.1
L-Histidine 71-00-1 0.16
L-Methionine 63-68-3 0.15
Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs. 9005-64-5 < 0.1
Acetic acid 64-19-7 < 0.1
Water 7732-18-5 > 91

SECTION 4. FIRST AID MEASURES

General advice: Do not leave the victim unattended.

If inhaled:
Move to fresh air.
If unconscious, place in recovery position and seek medical advice.
If symptoms persist, call a physician.

In case of skin contact:
If on skin, rinse well with water.

In case of eye contact:
Immediately flush eye(s) with plenty of water.
Remove contact lenses.
Protect unharmed eye.
If eye irritation persists, consult a specialist.

If swallowed:
Keep respiratory tract clear.
Do not give milk or alcoholic beverages.
Never give anything by mouth to an unconscious person.
If symptoms persist, call a physician.
Rinse mouth with water.

Most important symptoms and effects, both acute and delayed:
None known.

Notes to physician:
The first aid procedure should be established in consultation with the doctor responsible for industrial medicine.

SECTION 5. FIRE-FIGHTING MEASURES

Suitable extinguishing media:
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.

Specific hazards during firefighting:
No information available.

Hazardous combustion products:
No hazardous combustion products are known

Further information:
Standard procedure for chemical fires.
Use extinguishing measures that are appropriate to local circumstances and the surrounding environment.
SECTION 6. ACCIDENTAL RELEASE MEASURES

Personal precautions, protective equipment and emergency procedures: Avoid exposure. Refer to protective measures listed in sections 7 and 8.

Environmental precautions: Local authorities should be advised if significant spillages cannot be contained.

Methods and materials for containment and cleaning up: Wipe up with absorbent material (e.g. cloth, fleece). Keep in suitable, closed containers for disposal.

SECTION 7. HANDLING AND STORAGE

Advice on protection against fire and explosion: Normal measures for preventive fire protection.

Advice on safe handling: For personal protection see section 8. Smoking, eating and drinking should be prohibited in the application area.

Conditions for safe storage: Store between +2°C and +8°C. Do not freeze. Store protected from light. Do not shake solution. Electrical installations / working materials must comply with the technological safety standards.

Further information on storage conditions: See label, package insert or internal guidelines.

Materials to avoid: No materials to be especially mentioned.

Further information on storage stability: No decomposition if stored and applied as directed. Do not freeze. No decomposition if stored and applied as directed.

Packaging material: Suitable material: Ampoules, Prefilled syringes, Vials

SECTION 8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Ingredients with workplace control parameters

<table>
<thead>
<tr>
<th>Components</th>
<th>CAS-No.</th>
<th>Value type</th>
<th>Control parameter</th>
<th>Basis</th>
</tr>
</thead>
</table>

3 / 18
SAFETY DATA SHEET
LUNSUMIO Vials 30 mg/30 ml

<table>
<thead>
<tr>
<th>(Form of exposure)</th>
<th>Ters / Permissible concentration</th>
</tr>
</thead>
<tbody>
<tr>
<td>.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl</td>
<td>57-50-1</td>
</tr>
<tr>
<td>TWA (Respirable)</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>TWA (total)</td>
<td>10 mg/m³</td>
</tr>
<tr>
<td>TWA (total dust)</td>
<td>15 mg/m³</td>
</tr>
<tr>
<td>TWA (respirable fraction)</td>
<td>5 mg/m³</td>
</tr>
<tr>
<td>TWA (total dust)</td>
<td>15 mg/m³</td>
</tr>
<tr>
<td>TWA (respirable dust fraction)</td>
<td>5 mg/m³</td>
</tr>
</tbody>
</table>

Mosunetuzumab 1905409-39-3 IOEL 0.004 mg/m³ Roche Industrial Hygiene Committee (RIHC)

Engineering measures : No data available

Personal protective equipment
Respiratory protection : In the case of dust or aerosol formation use respirator with an approved filter.

No personal respiratory protective equipment normally required.

Hand protection
In case of contact through splashing:
Material : Nitrile rubber
Break through time : > 30 min
Glove thickness : > 0.11 mm

In case of full contact:
Material : butyl-rubber
Break through time : > 480 min
Glove thickness : > 0.4 mm

Remarks : Wear appropriate protective gloves to prevent skin contact. Replace torn or punctured gloves promptly.

Eye protection : Safety glasses

Skin and body protection : Protective suit

Protective measures : Instruction of employees recommended

Hygiene measures : Handle in accordance with good industrial hygiene and safety practice.
### SECTION 9. PHYSICAL AND CHEMICAL PROPERTIES

<table>
<thead>
<tr>
<th>Property</th>
<th>Value</th>
</tr>
</thead>
<tbody>
<tr>
<td>Appearance</td>
<td>Clear liquid</td>
</tr>
<tr>
<td>Color</td>
<td>colorless</td>
</tr>
<tr>
<td>Odor</td>
<td>No data available</td>
</tr>
<tr>
<td>Odor Threshold</td>
<td>No data available</td>
</tr>
<tr>
<td>pH</td>
<td>5.8</td>
</tr>
<tr>
<td>Melting point/range</td>
<td>No data available</td>
</tr>
<tr>
<td>Boiling point/boiling range</td>
<td>No data available</td>
</tr>
<tr>
<td>Flash point</td>
<td>does not flash</td>
</tr>
<tr>
<td>Evaporation rate</td>
<td>No data available</td>
</tr>
<tr>
<td>Self-ignition</td>
<td>Not applicable</td>
</tr>
<tr>
<td>Upper explosion limit / Upper flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Lower explosion limit / Lower flammability limit</td>
<td>No data available</td>
</tr>
<tr>
<td>Vapor pressure</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative vapor density</td>
<td>No data available</td>
</tr>
<tr>
<td>Relative density</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility(ies)</td>
<td></td>
</tr>
<tr>
<td>Water solubility</td>
<td>No data available</td>
</tr>
<tr>
<td>Solubility in other solvents</td>
<td>No data available</td>
</tr>
<tr>
<td>Partition coefficient: n-octanol/water</td>
<td>No data available</td>
</tr>
<tr>
<td>Autoignition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Decomposition temperature</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity</td>
<td></td>
</tr>
<tr>
<td>Viscosity, dynamic</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity, dynamic</td>
<td>No data available</td>
</tr>
<tr>
<td>Viscosity, kinematic</td>
<td>No data available</td>
</tr>
</tbody>
</table>
SAFE DATA SHEET

LUNSUMIO Vials 30 mg/30 ml

Explosive properties : No data available

SECTION 10. STABILITY AND REACTIVITY

Reactivity : No dangerous reaction known under conditions of normal use.

Chemical stability : Stable under normal conditions.

Does not contain any antimicrobial preservative; therefore, care must be taken to ensure the sterility of the prepared solution.

Proteins are temperature-sensitive; the thermal denaturation has an impact on quality but does not affect Plant and Process Safety; during decomposition no flammable gas, no organic peroxide and no oxidising substances are created.

Possibility of hazardous reactions : No data available

Stable under recommended storage conditions.

No hazards to be specially mentioned.

Conditions to avoid : No data available

Incompatible materials : No data available

Hazardous decomposition products : No decomposition if stored and applied as directed.

SECTION 11. TOXICOLOGICAL INFORMATION

Acute toxicity
Not classified based on available information.

Components:

Mosunetuzumab:
Acute oral toxicity : Remarks: Not bioavailable by oral administration

Acute toxicity (other routes of administration) : HNSTD (Highest Non-Severely Toxic Dose) (cynomolgus monkey): > 1 mg/kg Application Route: i.v. GLP: yes

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:
Acute oral toxicity : LD50 Oral (Rat): 29,700 mg/kg

L-Histidine:
Acute oral toxicity : LD50 Oral (Rat): > 15,000 mg/kg

LD50 Oral (Mouse): > 15,000 mg/kg

L-Methionine:
Acute oral toxicity : Acute toxicity estimate (Rat): > 5,000 mg/kg
SAFETY DATA SHEET

LUNSUMIO Vials 30 mg/30 ml

Version: 1.1
Revision Date: 02-06-2023
Date of last issue: 01-04-2021
Date of first issue: 01-04-2021

Method: Expert judgment

Acute toxicity estimate (Mouse): > 5,000 mg/kg
Method: Expert judgment

Acute inhalation toxicity: Acute toxicity estimate: > 30 mg/l
Test atmosphere: dust/mist
Method: Expert judgment

Acute dermal toxicity: Acute toxicity estimate: > 5,000 mg/kg
Method: Expert judgment

Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:
Acute oral toxicity: LD50 Oral (Rat): 38,900 mg/kg

Acetic acid:
Acute oral toxicity: LD50 Oral (Rat, male and female): 3,310 mg/kg
GLP: no

Acute inhalation toxicity: LC50 (Rat, male and female): 11.4 mg/l
Exposure time: 4 h
Test atmosphere: vapor
GLP: no
Assessment: The substance or mixture has no acute inhalation toxicity

Skin corrosion/irritation
Not classified based on available information.

Components:

L-Methionine:
Remarks: This information is not available.

Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:
Species: Rabbit
Result: No skin irritation

Acetic acid:
Species: Rabbit
Exposure time: 4 h
Method: OECD Test Guideline 404
Result: Causes severe burns.
GLP: No information available.

Serious eye damage/eye irritation
Not classified based on available information.

Components:

L-Methionine:
Remarks: This information is not available.
Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:
Species: Rabbit
Result: No eye irritation

Acetic acid:
Species: Rabbit
Result: Risk of serious damage to eyes.
Exposure time: 4 h
Method: OECD Test Guideline 405
GLP: No information available.

Respiratory or skin sensitization
Skin sensitization
Not classified based on available information.
Respiratory sensitization
Not classified based on available information.

Components:
Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:
Species: Guinea pig
Result: Not a skin sensitizer.

Germ cell mutagenicity
Not classified based on available information.

Components:
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:
Genotoxicity in vitro: Test Type: In vitro mammalian cell gene mutation test
Result: negative

Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:
Genotoxicity in vitro: Test Type: Micronucleus test
Test system: Escherichia coli
Result: negative

Germ cell mutagenicity - Assessment: Tests on bacterial or mammalian cell cultures did not show mutagenic effects.

Acetic acid:
Genotoxicity in vitro: Test Type: Microbial mutagenesis assay (Ames test)
Test system: Salmonella typhimurium
Metabolic activation: Metabolic activation
Method: OECD Test Guideline 471
Result: negative
GLP: No information available.
Remarks: In vitro tests did not show mutagenic effects
SAFETY DATA SHEET

LUNSUMIO Vials 30 mg/30 ml

Test Type: Chromosome aberration test in vitro
Test system: Chinese hamster ovary cells
Metabolic activation: with and without metabolic activation
Method: OECD Test Guideline 473
Result: negative
GLP: no
Remarks: In vitro tests did not show mutagenic effects

Genotoxicity in vivo
Test Type: Micronucleus test
Species: Rat (male and female)
Application Route: Inhalation
Exposure time: 13 weeks
Dose: 0, 1, 5, 20 ppm
Method: Mutagenicity (micronucleus test)
Result: negative
GLP: yes

Carcinogenicity
Not classified based on available information.

Components:

.alpha.-D-Glucopyranoside, beta.-D-fructofuranosyl:
Remarks: No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

L-Histidine:
Remarks: No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:
Remarks: No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

Acetic acid:
Species: Mouse, female
Application Route: Dermal
Exposure time: 32 weeks
Result: negative
GLP: no
Remarks: No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

IARC: No ingredient of this product present at levels greater than or equal to 0.1% is identified as probable, possible or confirmed human carcinogen by IARC.

OSHA: No component of this product present at levels greater than or equal to 0.1% is on OSHA’s list of regulated carcinogens.
SAFETY DATA SHEET

LUNSUMIO Vials 30 mg/30 ml

Version: 1.1
Revision Date: 02-06-2023
Date of last issue: 01-04-2021
Date of first issue: 01-04-2021

NTP: No ingredient of this product present at levels greater than or equal to 0.1% is identified as a known or anticipated carcinogen by NTP.

Reproductive toxicity
Not classified based on available information.

Components:

Mosunetuzumab:
Effects on fertility: Species: cynomolgus monkey
Result: No adverse effects.

Acetic acid:
Effects on fetal development: Species: Mouse, female
Application Route: Oral
Dose: 10 ml/kg body weight
Duration of Single Treatment: 6 - 15 d
Developmental Toxicity: NOAEL: 345 mg/kg body weight
GLP: No information available.

STOT-single exposure
Not classified based on available information.

Components:

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:
Assessment: The substance or mixture is not classified as specific target organ toxicant, single exposure.

L-Methionine:
Assessment: The substance or mixture is not classified as specific target organ toxicant, single exposure.

STOT-repeated exposure
Not classified based on available information.

Components:

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:
Assessment: The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

L-Methionine:
Assessment: The substance or mixture is not classified as specific target organ toxicant, repeated exposure.

Aspiration toxicity
Not classified based on available information.
Components:

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:
No data available

L-Methionine:
No data available

Further information

Components:

Mosunetuzumab:
Remarks : Globular proteins are generally well biodegradable

,alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:
Remarks : Health injuries are not known or expected under normal use.

SECTION 12. ECOLOGICAL INFORMATION

Ecotoxicity

Components:

.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:

Ecotoxicology Assessment
Acute aquatic toxicity : This product has no known ecotoxicological effects.
Chronic aquatic toxicity : This product has no known ecotoxicological effects.
Toxicity Data on Soil : Not expected to adsorb on soil.
Other organisms relevant to the environment : No data available

L-Methionine:
Toxicity to fish : LC50: > 100 mg/l
Exposure time: 96 h

Ecotoxicology Assessment
Acute aquatic toxicity : This product has no known ecotoxicological effects.
Chronic aquatic toxicity : This product has no known ecotoxicological effects.
Toxicity Data on Soil : Not expected to adsorb on soil.
Other organisms relevant to the environment : No data available

Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:
Toxicity to fish

LC50 (Oncorhynchus mykiss (rainbow trout)): 216 mg/l
Exposure time: 96 h

LC50 (Brachydanio rerio (zebrafish)): > 100 mg/l
Exposure time: 96 h
Method: OECD Test Guideline 203
GLP: yes

Exposure time: 96 h

Toxicity to daphnia and other aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 100 mg/l
Exposure time: 48 h

Toxicity to daphnia and other aquatic invertebrates (Chronic toxicity)

NOELR (Daphnia): 10 mg/l
Exposure time: 21 d
Method: OECD Test Guideline 211

Toxicity to microorganisms

EC0 (Pseudomonas putida): > 10,000 mg/l
Exposure time: 5 h

Acetic acid:

Toxicity to fish

LC50 (Oncorhynchus mykiss (rainbow trout)): > 300.82 mg/l
End point: mortality
Exposure time: 96 h
Test Type: semi-static test
Analytical monitoring: no
Method: OECD Test Guideline 203
GLP: yes

Toxicity to daphnia and other aquatic invertebrates

EC50 (Daphnia magna (Water flea)): > 300.82 mg/l
End point: Immobilization
Exposure time: 48 h
Test Type: static test
Analytical monitoring: yes
Method: OECD Test Guideline 202
GLP: yes

Toxicity to algae/aquatic plants

EC50 (Skeletonema costatum (marine diatom)): > 300.82 mg/l
Exposure time: 72 h
Test Type: static test
Analytical monitoring: no
GLP: yes

Persistence and degradability

Components:

Mosunetuzumab:
Biodegradability: Result: Globular proteins are generally well biodegradable

Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:
Biodegradability: Result: Readily biodegradable.
Biodegradation: > 70 %
Exposure time: 28 d
SAFETY DATA SHEET

LUNSUMIO Vials 30 mg/30 ml

Version 1.1  Revision Date: 02-06-2023  Date of last issue: 01-04-2021
Date of first issue: 01-04-2021

Method: OECD Test Guideline 301B

**Acetic acid:**

Biodegradability: aerobic
Inoculum: activated sludge
Concentration: 3 mg/l
Result: Readily biodegradable.
Biodegradation: 96%
Exposure time: 20 d
GLP: no

**Bioaccumulative potential**

**Components:**

**Mosunetuzumab:**
Partition coefficient: n-octanol/water: Remarks: No data available

**.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl:**
Partition coefficient: n-octanol/water: log Pow: -3.7 (68 °F / 20 °C)

**L-Histidine:**
Partition coefficient: n-octanol/water: Remarks: Not applicable

**L-Methionine:**
Partition coefficient: n-octanol/water: log Pow: -1.87

**Sorbitan, monododecanoate, poly(oxy-1,2-ethanediyl) derivs.:**
Bioaccumulation: Remarks: No data available
Partition coefficient: n-octanol/water: Remarks: No data available

**Acetic acid:**
Bioaccumulation: Bioconcentration factor (BCF): 3.16
Partition coefficient: n-octanol/water: log Pow: -0.17 (77 °F / 25 °C)
pH: 7
Method: No information available.
GLP: No information available.

**Water:**
Partition coefficient: n-octanol/water: Remarks: No data available
Mobility in soil
No data available

Other adverse effects

Product:
Ozone-Depletion Potential : Regulation: 40 CFR Protection of Environment; Part 82 Protection of Stratospheric Ozone - CAA Section 602 Class I Substances
Remarks: This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).

Components:

Mosunetuzumab:
Additional ecological information : Monoclonal antibodies are proteins with highly specific affinity to a certain antigen; therefore, no appreciable ecotoxic potential is to be expected

L-Histidine:
Additional ecological information : No data available

L-Methionine:
Adsorbed organic bound halogens (AOX) : Remarks: Not applicable
Additional ecological information : No data available

SECTION 13. DISPOSAL CONSIDERATIONS

Disposal methods
Waste from residues : Can be disposed as waste water, when in compliance with local regulations.

Contaminated packaging : Empty containers should be taken to an approved waste handling site for recycling or disposal. Do not re-use empty containers.

SECTION 14. TRANSPORT INFORMATION

International Regulations

UNRTDG
Not regulated as a dangerous good

IATA-DGR
Not regulated as a dangerous good
IMDG-Code
Not regulated as a dangerous good

Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code
Not applicable for product as supplied.

Domestic regulation

49 CFR
Not regulated as a dangerous good

Special precautions for user
Remarks : Not dangerous goods in the meaning of ADR/RID, ADN, IMDG-Code, ICAO/IATA-DGR

SECTION 15. REGULATORY INFORMATION

CERCLA Reportable Quantity
Listed substances in the product are at low enough levels to not be expected to exceed the RQ

SARA 304 Extremely Hazardous Substances Reportable Quantity
This material does not contain any components with a section 304 EHS RQ.

SARA 302 Extremely Hazardous Substances Threshold Planning Quantity
This material does not contain any components with a section 302 EHS TPQ.

SARA 311/312 Hazards : No SARA Hazards

SARA 313 : This material does not contain any chemical components with known CAS numbers that exceed the threshold (De Minimis) reporting levels established by SARA Title III, Section 313.

Clean Air Act
This product neither contains, nor was manufactured with a Class I or Class II ODS as defined by the U.S. Clean Air Act Section 602 (40 CFR 82, Subpt. A, App.A + B).
This product does not contain any hazardous air pollutants (HAP), as defined by the U.S. Clean Air Act Section 112 (40 CFR 61).
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 112(r) for Accidental Release Prevention (40 CFR 68.130, Subpart F).
This product does not contain any chemicals listed under the U.S. Clean Air Act Section 111 SOMCI Intermediate or Final VOC's (40 CFR 60.489).

Clean Water Act
The following Hazardous Substances are listed under the U.S. CleanWater Act, Section 311, Table 116.4A:

<table>
<thead>
<tr>
<th>Acetic acid</th>
<th>64-19-7</th>
<th>&gt;= 0 - &lt; 0.1 %</th>
</tr>
</thead>
</table>

The following Hazardous Chemicals are listed under the U.S. CleanWater Act, Section 311, Table 117.3:

<table>
<thead>
<tr>
<th>Acetic acid</th>
<th>64-19-7</th>
<th>&gt;= 0 - &lt; 0.1 %</th>
</tr>
</thead>
</table>

This product does not contain any toxic pollutants listed under the U.S. Clean Water Act Section 307
This product does not contain any priority pollutants related to the U.S. Clean Water Act
SAFETY DATA SHEET

LUNSUMIO Vials 30 mg/30 ml

Version 1.1
Revision Date: 02-06-2023
Date of last issue: 01-04-2021
Date of first issue: 01-04-2021

US State Regulations

Massachusetts Right To Know
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

Pennsylvania Right To Know
Water 7732-18-5
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1
Acetic acid 64-19-7

Maine Chemicals of High Concern
Product does not contain any listed chemicals

Vermont Chemicals of High Concern
Product does not contain any listed chemicals

Washington Chemicals of High Concern
Product does not contain any listed chemicals

California Permissible Exposure Limits for Chemical Contaminants
.alpha.-D-Glucopyranoside, .beta.-D-fructofuranosyl 57-50-1

The ingredients of this product are reported in the following inventories:

AIIC : Not in compliance with the inventory

DSL : This product contains the following components that are not on the Canadian DSL nor NDSL.
Mosunetuzumab

NZIoC : On the inventory, or in compliance with the inventory

ENCS : Not in compliance with the inventory

ISHL : Not in compliance with the inventory

KECI : Not in compliance with the inventory

PICCS : Not in compliance with the inventory

IECSC : Not in compliance with the inventory

TCSI : Not in compliance with the inventory

TSCA : Product contains substance(s) not listed on TSCA inventory.

TECI : Not in compliance with the inventory

TSCA list
No substances are subject to a Significant New Use Rule.

No substances are subject to TSCA 12(b) export notification requirements.

SECTION 16. OTHER INFORMATION

16 / 18
SAFETY DATA SHEET

LUNSUMIO Vials 30 mg/30 ml

Version 1.1
Revision Date: 02-06-2023
Date of last issue: 01-04-2021
Date of first issue: 01-04-2021

NFPA 704:

HMIS® IV:

<table>
<thead>
<tr>
<th>HEALTH</th>
<th>FLAMMABILITY</th>
<th>PHYSICAL HAZARD</th>
</tr>
</thead>
<tbody>
<tr>
<td>/</td>
<td>0</td>
<td>0</td>
</tr>
</tbody>
</table>

HMIS® ratings are based on a 0-4 rating scale, with 0 representing minimal hazards or risks, and 4 representing significant hazards or risks. The "*" represents a chronic hazard, while the "/'" represents the absence of a chronic hazard.

Full text of other abbreviations

ACGIH : USA. ACGIH Threshold Limit Values (TLV)
NIOSH REL : USA. NIOSH Recommended Exposure Limits
OSHA P0 : USA. Table Z-1-A Limits for Air Contaminants (1989 vacated values)
OSHA Z-1 : USA. Occupational Exposure Limits (OSHA) - Table Z-1 Limits for Air Contaminants
ACGIH / TWA : 8-hour, time-weighted average
NIOSH REL / TWA : Time-weighted average concentration for up to a 10-hour workday during a 40-hour workweek
OSHA P0 / TWA : 8-hour time weighted average
OSHA Z-1 / TWA : 8-hour time weighted average

AIIIC - Australian Inventory of Industrial Chemicals; ASTM - American Society for the Testing of Materials; bw - Body weight; CERCLA - Comprehensive Environmental Response, Compensation, and Liability Act; CMR - Carcinogenic, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DOT - Department of Transportation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; EHS - Extremely Hazardous Substance; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; HMIS - Hazardous Materials Identification System; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; MSHA - Mine Safety and Health Administration; n.o.s. - Not Otherwise Specified; NFPA - National Fire Protection Association; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office
SAFETY DATA SHEET

**LUNSUMIO Vials 30 mg/30 ml**

<table>
<thead>
<tr>
<th>Version</th>
<th>Revision Date:</th>
<th>Date of last issue: 01-04-2021</th>
</tr>
</thead>
<tbody>
<tr>
<td>1.1</td>
<td>02-06-2023</td>
<td>Date of first issue: 01-04-2021</td>
</tr>
</tbody>
</table>

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information given is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and is not to be considered a warranty or quality specification. The information relates only to the specific material designated and may not be valid for such material used in combination with any other materials or in any process, unless specified in the text.

**Revision Date**: 02-06-2023

US / Z8 / 2204